Chorioretinal ischemia and angiogenic milieu following photodynamic therapy

Current Eye Research

Volumn 35, Issue 4, 2010, Pages 314-321

  Moon, Jun Woong ^a,b   Kim, Young Joo ^a   Khwarg, Sang In ^a   Chung, Hum ^a   Yu, Hyeong Gon ^a  

^a Seoul National University   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

Chorioretinal ischemia; Hypoxia inducible factor; Insulin like growth factor; Photodynamic therapy; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; HYPOXIA INDUCIBLE FACTOR; PIMONIDAZOLE; SOMATOMEDIN; VASCULOTROPIN; VERTEPORFIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHORIORETINAL ISCHEMIA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DIODE LASER; ENUCLEATION; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE; IRRADIATION; ISCHEMIA; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECURRENT DISEASE;

ANGIOGENIC PROTEINS; ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIA; MICROSCOPY, CONFOCAL; NITROIMIDAZOLES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RATS; RATS, INBRED BN; RETINAL DISEASES; RETINAL VESSELS; SOMATOMEDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950796653     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903548962     Document Type: Article

References (35)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
2. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
3. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
4. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP Report No. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-1142.
5. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049-1061.
6. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-457.
7. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy Report 2. Am J Ophthalmol. 2001; 131: 541-560.
8. Ferrario A, von Tiehl KF, Rucker N, et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000;60:4066-4069.
9. Jiang F, Zhang ZG, Katakowski M, et al. Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem Photobiol. 2004;79:494-498.
10. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: Effects of fluence rate. Br J Cancer. 1998;77:1386-1394.
11. Engbrecht BW, Menon C, Kachur AV, et al. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res. 1999;59:4334-4342.
12. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473-4480.
13. Starita C, Hussain AA, Pagliarini S, et al. Hydrodynamics of aging Bruch's membrane: Implications for macular disease. Exp Eye Res. 1996;62:565-572.
14. Grunwald JE, Hariprasad SM, DuPont J, et al. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1998;39:385-390.
15. Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005;46:1033-1038.
16. Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: Angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384-2391.
17. Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina. 2007;27:713-723. (Pubitemid 47053860)
18. Arteel GE, Thurman RG, Yates JM, et al. Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 1995;72:889-895.
19. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem. 1998;253:743-750.
20. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
21. Lambooij AC, van Wely KH, Lindenbergh-Kortleve DJ, et al. Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2003;44:2192-2198.
22. Gilpin DA. Calculation of a new Meeh constant and experimental determination of burn size. Burns. 1996;22:607-611.
23. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142:95-104.
24. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol. 2006;124:815-823. (Pubitemid 43877675)
25. Huang Z, Chen Q, Shakil A, et al. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol. 2003;78:496-502.
26. Fingar VH, Mang TS, Henderson BW. Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice. Cancer Res. 1988;48:3350-3354.
27. Chen B, Xu Y, Agostinis P, et al. Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells. Int J Oncol. 2001;18:1279-1285.
28. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol. 1999;117:1329-1345.
29. Huang LE, Gu J, Schau M, et al. Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998;95:7987-7992.
30. Chang TC, Huang CJ, Tam K, et al. Stabilization of hypoxia-inducible factor-1{alpha} by prostacyclin under prolonged hypoxia via reducing reactive oxygen species level in endothelial cells. J Biol Chem. 2005;280:36567-36574.
31. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun. 2002;291:908-914.
32. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830-841. (Pubitemid 34184504)
33. Schlötzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748-757.
34. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2331.
35. Ciulla TA, Criswell MH, Snyder WJ, et al. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol. 2005;89:113-119.